首页|局部晚期宫颈癌同步放化疗两种化疗方案疗效及不良反应比较

局部晚期宫颈癌同步放化疗两种化疗方案疗效及不良反应比较

扫码查看
目的 比较局部晚期宫颈癌同步放化疗顺铂联合多西他赛与经典单药顺铂两种化疗方案的疗效及毒副作用.方法 选择2010年~2014年间西安医学院附属宝鸡医院行同步放化疗的中晚期宫颈癌(ⅡB-ⅣA期)患者48例,所有患者均选择3DCRT技术盆腔外照射联合腔内后装治疗,放疗剂量均达根治量.根据同期化疗方案分为顺铂联合多西他赛组(A组,n=24),具体用药情况:顺铂60 mg/(m2?d)静脉滴注d1,或分2天,多西他赛60 mg/(m2?d)静脉滴注d1,每21天重复,共3周期;单药顺铂化疗组(B组,n=24),顺铂40 mg/(m2?d)静脉滴注,每周1次,共5~6周.比较2组患者近期与远期临床疗效及放化疗不良反应.结果 A组和B组的治疗近期有效率分别为91.7%和87.5%,差别无统计学意义;2年无进展生存期分别为75.00%和54.2%,差别有统计学意义(P<0.05);2组中Ⅲ、Ⅳ度血液学毒性反应发生率分别为45.9%、33.3%,差别有统计学意义(P<0.05),Ⅲ、Ⅳ度急性及晚期下消化道反应、泌尿系反应发生率差异无统计学意义.结论 局部晚期宫颈癌根治性放疗同期顺铂联合多西他赛与单药顺铂化疗方案比较近期疗效无显著差异,2年无进展生存率明显高于单药顺铂组,但顺铂联合多西他赛组放化疗血液学毒副反应较明显,非血液学放化疗不良反应2组比较差异无统计学意义.
Comparison of efficacy and adverse reaction of two chemotherapy regimens for locally advanced cervical cancer with concurrent chemoradiotherapy
Objective To compare the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin and docetaxel in combination with classical single drug cisplatin in locally advanced cervical cancer. Methods From 2010 to 2014 in Baoji hospital affiliated to Xi'an medical university, 48 patients with advanced cervical cancer( stage II B-stage IV A), who received concurrent chemoradiotherapy were selected, all patients were treated with 3DCRT technique, pelvic external irradiation combined with intracavitary brachytherapy, the dose of radiotherapy reached a radical dose. According to the same chemotherapy divided into docetaxel cisplatin group (group A, n=24), specific drugs: Cisplatin 60mg/ (m2?d) d1 intravenous drip, or 2 days, docetaxel 60mg/ (m2?d) d1 intravenous drip, repeated every 21 days, a total of 3 cycles of cisplatin group; (group B, n=24), cisplatin 40mg/(m2?d)intravenous drip, 1 times a week, a total of 5~6 weeks. The long-term clinical efficacy and adverse effects of radiotherapy and chemotherapy were compared between the two groups. Results The recent effective rate in group A and group B respectively were 91.7 % and 87.5%, the difference was not statistically significant; 2 year progression free survival in group A and group B respectively was 75.00 %and 54.2 %, the difference was statistically significant (P<0.05); Grade III and IV hematologic toxicity in group A and group B respectively was 45.9 %, 33.3 %, the differenc was statistically significant , (P<0.05). Acute and late gastrointestinal reactions, urinary tract reaction rate in the two groups had no significant difference. Conclusion There was no significant difference between radical radiotherapy and cisplatin combined with docetaxel and cisplatin for locally advanced cervical cancer and compare the efficacy, 2 year progression free survival rate was significantly higher than single drug cisplatin group and cisplatin combined with docetaxel chemotherapy group but hematologic toxicities were obvious, and non-hematologic adverse reactions of radiotherapy and chemotherapy without significant difference.

Locally advanced cervical cancerconcurrent chemoradiotherapycisplatindocetaxel

杨雪

展开 >

西安医学院附属宝鸡医院 肿瘤科,陕西 宝鸡 721006

局部晚期宫颈癌 同步放化疗 顺铂 多西他赛

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(10)
  • 2
  • 8